ADIMAB

ADIMAB

Adimab’s yeast-based discovery platform functions as a synthetic human immune system to create novel antibody therapeutics across an extensive range of diseases, including cancer as well as autoimmune and infectious diseases. We are a profitable privately-held biotech company, backed by top-tier venture capital firms including Google Ventures, OrbiMed Advisors, Polaris Partners, and SV Life Sciences. We are unique in our ability to take a long-term view on value creation which allows us to continuously refine and improve our technology and make substantial investments in R&D.